NCT04515238
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04515238
Title Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)
Acronym CLL2-BZAG
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors German CLL Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Hamatologische/Onkologische Gemeinschaftspraxis Augsburg 86150 Germany Details
Universitätsklinik Köln Cologne 50937 Germany Details
Onkologische Schwerpunktpraxis Esslingen am Neckar 73728 Germany Details
Evangelische Krankenhaus Hamm Hamm 59063 Germany Details
Universitaetskliniken des Saarlandes Homburg 66424 Germany Details
Universitaetsklinikum Schleswig-Holstein Campus Kiel Kiel 24105 Germany Details
KH Kliniken Maria Hilf Mönchengladbach 41063 Germany Details
Klinikum Rechts der Isar - Technische Universitaet Muenchen Munich 81675 Germany Details
Stauferklinikum Schwaebisch-Gmuend Mutlangen 73557 Germany Details
Universitätsklinik Ulm Ulm 89081 Germany Details
Hämatologisch Onkologische Schwerpunktpraxis Würzburg 97080 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field